Ultra-fast carbon ion radiation for prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial uses a special type of radiation called carbon ion therapy given in just 4 sessions (ultra-hypofractionated) to treat prostate cancer. It aims to see if this short treatment is safe and effective for men with low or intermediate risk prostate cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a man aged 19 or older.
- You must have prostate cancer confirmed by biopsy in the last 6 months.
- Your cancer must be low or intermediate risk (based on PSA, Gleason score, and tumor stage).
- You cannot have cancer that has spread to lymph nodes or other parts of your body.
- You need to be in good general health (able to do daily activities without help).
- You must have had a special prostate MRI before your biopsy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests radiation therapy for men with very high-risk prostate cancer that hasn't spread. It aims to see if targeting the tumor with radiation can help control the cancer in this highest risk group.
This trial tests a shorter course of radiation therapy with an extra 'boost' to the most aggressive part of the tumor, combined with hormone therapy, for men with high-risk or locally advanced prostate cancer that has not spread outside the pelvis.
This trial tests a high-precision radiation treatment (CyberKnife SBRT) for prostate cancer that is still within the prostate. It aims to see if a very short course of radiation works well with fewer side effects.
This trial tests a shorter course of radiation therapy (hypofractionated radiotherapy) for men who have already had their prostate removed and still have signs of cancer (like rising PSA). The goal is to see if this can help prevent the cancer from coming back.
This trial studies a more sped-up radiation schedule for men with certain local prostate cancers, given together with hormone therapy. It aims to keep cancer control while possibly reducing treatment time and making care easier.
This trial studies a type of focused radiation (“ablative radiotherapy”) for prostate tumors considered intermediate- or high-risk. It may help improve control of the cancer while aiming for acceptable side effects.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.